Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study - Patrikidou, Anna; Saieva, Calogero; Lee-Ying, Richard; Nuzzo, Pier Vitale; Zarif, Talal El; McClure, Heather; Davidsohn, Matthew; Eid, Marc; Spinelli, Gian Paolo; Catalano, Fabio; Cremante, Malvina; Fotia, Giuseppe; et al. (Clinical Genitourinary Cancer, 2024)